Curis Prices $8.5 Million Private Placement

By Public Technologies
  • Curis priced an $8.5 million private placement with existing healthcare-focused institutional investors, expected to close around October 19, 2026.
  • The offering comprises 16,666,680 common shares or pre-funded warrants at $0.51 each, including an accompanying common warrant.
  • Common warrants cover 16,666,680 shares at $0.60 each, becoming exercisable after six months and expiring five-and-a-half years from issuance.
  • Existing January 2026 and August 2026 warrants will have exercise prices reduced to $0.60 from $15 and $1.75, respectively.
  • Proceeds will fund research and operations through initial chronic lymphocytic leukemia data from 5-10 patients expected in December 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610160800PR_NEWS_USPR_____NE74019) on October 16, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.